| Typicality: | 0.235 |
| Saliency: | 0.169 |
| successfully | 4 | manner |
| compound → completed → phase ii clinical trials | 4 |
| compound → be in → phase ii clinical trials | 3 |
| negative | neutral | positive |
| 0.023 | 0.480 | 0.496 |
| Raw frequency | 7 |
| Normalized frequency | 0.169 |
| Modifier score | 0.500 |
| Perplexity | 86.483 |